Page 1716 - Williams Hematology ( PDFDrive )

1690 Part XI: Malignant Lymphoid Diseases Chapter 103: Cutaneous T-Cell Lymphoma (Mycosis Fungoides and Sézary Syndrome) 1691

115. Olsen EA, Kim YH, Kuzel TM, et al: Phase IIb multicenter trial of vorinostat in patients 135. Spigel SC, Coltman CA, Jr: Therapy of mycosis fungoides with bleomycin. Cancer
with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin 32:767–770, 1973.
Oncol 25:3109–3115, 2007. 136. Levi JA, Diggs CH, Wiernik PH: Adriamycin therapy in advanced mycosis fungoides.
116. Piekarz RL, Frye R, Turner M, et al: Phase II multi-institutional trial of the histone Cancer 39:1967–1970, 1977.
deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell 137. Wollina U, Dummer R, Brockmeyer NH, et al: Multicenter study of pegylated liposomal
lymphoma. J Clin Oncol 27:5410–5417, 2009. doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001, 2003.
117. Olsen EA: Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 138. Foss FM: Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: Single-agent
16:311–321, 2003. and combination studies. Semin Oncol 27:58–63, 2000.
118. Wozniak MB, Tracey L, Ortiz-Romero PL, et al: Psoralen plus ultraviolet A +/- interferon-alpha 139. Kurzrock R: Therapy of T cell lymphomas with pentostatin. Ann N Y Acad Sci 941:200–205,
treatment resistance in mycosis fungoides: The role of tumour microenvironment, 2001.
nuclear transcription factor-kappaB and T-cell receptor pathways. Br J Dermatol 160: 140. Quaglino P, Fierro MT, Rossotto GL, et al: Treatment of advanced mycosis fungoides/
92–102, 2009. Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extra-
119. Rupoli S, Goteri G, Pulini S, et al: Long-term experience with low-dose interferon-alpha and corporeal photochemotherapy. Br J Dermatol 150:327–336, 2004.
PUVA in the management of early mycosis fungoides. Eur J Haematol 75:136–145, 2005. 141. Zinzani PL, Baliva G, Magagnoli M, et al: Gemcitabine treatment in pretreated cutane-
120. Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by ous T-cell lymphoma: Experience in 44 patients. J Clin Oncol 18:2603–2606, 2000.
extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316:297–303, 142. Vonderheid EC: Treatment of cutaneous T cell lymphoma: 2001. Recent Results Cancer
1987. Res 160:309–320, 2002.
121. Knobler R, Girardi M: Extracorporeal photochemoimmunotherapy in cutaneous T cell 143. Abd-el-Baki J, Demierre MF, Li N, et al: Transformation in mycosis fungoides: The role
lymphomas. Ann N Y Acad Sci 941:123–138, 2001. of methotrexate. J Cutan Med Surg 6:109–116, 2002.
122. Knobler R, Duvic M, Querfeld C, et al: Long-term follow-up and survival of cutaneous 144. Kaye FJ, Bunn PA Jr, Steinberg SM, et al: A randomized trial comparing combination
T-cell lymphoma patients treated with extracorporeal photopheresis. Photodermatol electron-beam radiation and chemotherapy with topical therapy in the initial treatment
Photoimmunol Photomed 28:250–257, 2012. of mycosis fungoides. N Engl J Med 321:1784–1790, 1989.
123. Talpur R, Demierre MF, Geskin L, et al: Multicenter photopheresis intervention trial in 145. Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sezary syndrome.
early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk 11:219–227, 2011. Hematol Oncol Clin North Am 9:1109–1116, 1995.
124. Kennedy GA, Seymour JF, Wolf M, et al: Treatment of patients with advanced mycosis 146. Vonderheid EC: Treatment planning in cutaneous T-cell lymphoma. Dermatol Ther
fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 71:250–256, 2003. 16:276–282, 2003.
125. Lundin J, Hagberg H, Repp R, et al: Phase 2 study of alemtuzumab (anti-CD52 mono- 147. Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lympho-
clonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood mas. Semin Hematol 40:244–256, 2003.
101:4267–4272, 2003. 148. Willemze R, Beljaards RC: Spectrum of primary cutaneous CD30 (Ki-1)-positive lym-
126. Alinari L, Geskin L, Grady T, et al: Subcutaneous alemtuzumab for Sézary syndrome in phoproliferative disorders. A proposal for classification and guidelines for management
the very elderly. Leuk Res 32:1299–1303, 2008. and treatment. J Am Acad Dermatol 28:973–980, 1993.
127. Bernengo MG, Quaglino P, Comessatti A, et al: Low-dose intermittent alemtuzumab in 149. Bergman R, Marcus-Farber BS, Manov L, et al: Clinicopathologic reassessment of
the treatment of Sézary syndrome: Clinical and immunologic findings in 14 patients. non-mycosis fungoides primary cutaneous lymphomas during 17 years. Int J Dermatol
Haematologica 92:784–794, 2007. 41:735–743, 2002.
128. Mehra T, Ikenberg K, Moos RM, et al: Brentuximab as a treatment for CD30+ mycosis 150. Tomaszewski MM, Moad JC, Lupton GP: Primary cutaneous Ki-1(CD30) positive
fungoides and Sézary syndrome. JAMA Dermatol 151:73–77, 2014. anaplastic large cell lymphoma in childhood. J Am Acad Dermatol 40:857–861, 1999.
129. Negro-Vilar A, Dziewanowska Z, Groves ES, et al: Efficacy and safety of denileukin 151. Gorczyca W, Tsang P, Liu Z, et al: CD30-positive T-cell lymphomas co-expressing
diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients CD15: An immunohistochemical analysis. Int J Oncol 22:319–324, 2003.
with cutaneous T-cell lymphoma (CTCL). J Clin Oncol 25:8026, 2007. 152. Jaffe ES: Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopa-
130. Horwitz SM, Kim YH, Foss F, et al: Identification of an active, well-tolerated dose of thology. Mod Pathol 14:219–228, 2001.
pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 153. DeCoteau JF, Butmarc JR, Kinney MC, et al: The t(2;5) chromosomal translocation is
119:4115–4122, 2012. not a common feature of primary cutaneous CD30+ lymphoproliferative disorders:
131. Koch E, Story SK, Geskin LJ: Preemptive leucovorin administration minimizes prala- Comparison with anaplastic large-cell lymphoma of nodal origin. Blood 87:3437–3441,
trexate toxicity without sacrificing efficacy. Leuk Lymphoma 54:2448–2451, 2013. 1996.
132. Van Scott EJ, Grekin DA, Kalmanson JD, et al: Frequent low doses of intravenous 154. El Shabrawi-Caelen L, Kerl H, Cerroni L: Lymphomatoid papulosis: Reappraisal of
mechlorethamine for late-stage mycosis fungoides lymphoma. Cancer 36:1613–1618, clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol
1975. 140:441–447, 2004.
133. Van Scott EJ, Auerbach R, Clendenning WE: Treatment of mycosis fungoides with 155. Wang HH, Myers T, Lach LJ, et al: Increased risk of lymphoid and nonlymphoid malig-
cyclophosphamide. Arch Dermatol 85:499–501, 1962. nancies in patients with lymphomatoid papulosis. Cancer 86:1240–1245, 1999.
134. Zackheim HS, Kashani-Sabet M, Hwang ST: Low-dose methotrexate to treat ery- 156. Liu HL, Hoppe RT, Kohler S, et al: CD30+ cutaneous lymphoproliferative disorders:
throdermic cutaneous T-cell lymphoma: Results in twenty-nine patients. J Am Acad The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic
Dermatol 34:626–631, 1996. large cell lymphoma. J Am Acad Dermatol 49:1049–1058, 2003.

Kaushansky_chapter 103_p1679-1692.indd 1691 9/21/15 12:51 PM